×

1 year of JLINX
Catalyst for innovations in healthcare receives European and Flemish support

Johnson & Johnson Innovation, JLINX (JLINX) is one year old today. With financial support from European (ERDF) and Flemish (VLAIO – Hermes) organisations, JLINX has just expanded its community to seven companies.

JLINX was launched in April 2016 by Janssen Pharmaceutica in collaboration with Bioqube Ventures. A new investment and incubation model, JLINX was developed to give a start and support to fledgling companies and projects that have the potential to bring about significant transformations in the field of healthcare.

JLINX provides young entrepreneurs with a unique combination of resources: venture capital, infrastructure and collaborations with organisations in the European ecosystem. The aim is to develop scientific discoveries at an accelerated pace and realise breakthroughs in healthcare. JLINX is located on the Janssen Campus in Beerse, Belgium and is managed by Bioqube Ventures. They monitor the selection of the companies for the venture capital investments.

‘The mission of Johnson & Johnson Innovation is to start up and further develop the most promising science—from inside or outside the company—to create solutions for patients and consumers all around the globe,’ explains Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. Since starting, the JLINX community has already welcomed seven companies that are performing highly promising research in the areas of microbiome, oncology and new discovery platforms. The aim is to expand the community to twenty companies within three years.

In the last year, JLINX has benefited from 2.1 million euro of financial support from the European Regional Development Fund (ERDF) and the government agency Flanders Innovation & Entrepreneurship (VLAIO – Hermesfonds). ‘This is an extra boost towards making these ambitions a reality. It helps to put this region on the map as a powerful player in healthcare. This way, groundbreaking medical innovations come more quickly to the people who need them. And at the end of the day, that’s what it’s all about,’ states Stef Heylen, M.D., Chief Operations Officer, Janssen R&D and Managing Director, Janssen Pharmaceutica.

For more information about JLINX, go to https://www.jnjinnovation.com/jlinx

Media contact

Frederik Wittock
Director Communication EMEA, Johnson & Johnson Innovation – +32 (0) 476 92 50 77

Tim De Kegel
Communication & Public Affairs Leader Benelux, Janssen Belgium – +32 (0) 473 74 60 28

Debora Dumont
Managing Partner, Bioqube Ventures – +32 (0) 477 25 22 16